Abstract
In recent years, two different methods have been developed to image cell proliferation with the functional imaging technique, Positron emission Tomography (PET), proliferation rate and proliferative status. Proliferation rate is a measure of the tumor doubling time and uses radiolabeled analogs of the DNA precursor thymidine. This approach measures the activity of the enzyme thymidine kinase 1 (TK1) and provides a pulse label of the S phase fraction of a tumor. Proliferative status provides a measure of the ratio of proliferating (P) and quiescent (Q) cells in a tumor. This imaging approach for measuring proliferative status involves measuring the sigma-2 (σ2) receptor status of a tumor, the only protein which has been validated for making this measurement in vivo with PET. This article provides an overview of the biological information obtained from these different imaging strategies, and the development of radiotracers for imaging proliferation rate and proliferative status.
Keywords: Cell proliferation, DNA synthesis, positron emission tomography, radiotracer, sigma-2 receptors.
Current Topics in Medicinal Chemistry
Title:Development of 18F-Labeled PET Probes for Imaging Cell Proliferation
Volume: 13 Issue: 8
Author(s): Kiran Kumar Solingapuram Sai, Lynne A. Jones and Robert H. Mach
Affiliation:
Keywords: Cell proliferation, DNA synthesis, positron emission tomography, radiotracer, sigma-2 receptors.
Abstract: In recent years, two different methods have been developed to image cell proliferation with the functional imaging technique, Positron emission Tomography (PET), proliferation rate and proliferative status. Proliferation rate is a measure of the tumor doubling time and uses radiolabeled analogs of the DNA precursor thymidine. This approach measures the activity of the enzyme thymidine kinase 1 (TK1) and provides a pulse label of the S phase fraction of a tumor. Proliferative status provides a measure of the ratio of proliferating (P) and quiescent (Q) cells in a tumor. This imaging approach for measuring proliferative status involves measuring the sigma-2 (σ2) receptor status of a tumor, the only protein which has been validated for making this measurement in vivo with PET. This article provides an overview of the biological information obtained from these different imaging strategies, and the development of radiotracers for imaging proliferation rate and proliferative status.
Export Options
About this article
Cite this article as:
Sai Kiran Kumar Solingapuram, Jones Lynne A. and Mach Robert H., Development of 18F-Labeled PET Probes for Imaging Cell Proliferation, Current Topics in Medicinal Chemistry 2013; 13 (8) . https://dx.doi.org/10.2174/1568026611313080003
DOI https://dx.doi.org/10.2174/1568026611313080003 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microbubble-Assisted p53, RB, and p130 Gene Transfer in Combination with Radiation Therapy in Prostate Cancer
Current Gene Therapy Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Heterologous Expression and Application of Multicopper Oxidases from <i>Enterococcus</i> spp. for Degradation of Biogenic Amines
Protein & Peptide Letters Medicinal and Cosmetic Potentials of Sophorolipids
Mini-Reviews in Medicinal Chemistry New Molecules as Drug Candidates for the Treatment of Upper and Lower GI Tract Ulcers
Current Pharmaceutical Design MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Editorial [Hot Topic: Emerging Drugs in Gastrointestinal Tract (Executive Guest Editor: Predrag Sikiric)]
Current Pharmaceutical Design Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Fibrinogen Alpha Chain Acts as a HBsAg Binding Protein and their Interaction Promotes HepG2 Cell Apoptosis
Current Proteomics Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans
Current Genomics Patents in miRNAs Biomarkers for Gastrointestinal Cancer Diagnostics
Recent Patents on Biomarkers Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Letters in Drug Design & Discovery Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation
Current Drug Targets Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Patent Selections:
Recent Patents on Biomarkers Irritable Bowel Syndrome: A Clinical Review
Current Rheumatology Reviews Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers